中國泰凌醫(yī)藥集團(tuán)始創(chuàng)于1995年，是一家集研發(fā)、生產(chǎn)、銷售為一體的國際化制藥集團(tuán)公司，在香港聯(lián)合交易所主板上市（股份代號：01011.HK）。集團(tuán)總部位于香港，在上海設(shè)有投資及營銷管理中心，在北京設(shè)有研發(fā)及醫(yī)學(xué)事務(wù)中心，在蘇州、泰州、長沙及瑞士建有生產(chǎn)基地，擁有10余家全資或控股的生產(chǎn)及銷售公司。
集團(tuán)的核心產(chǎn)品覆蓋了腫瘤及血液系統(tǒng)疾病、骨代謝疾病、消化系統(tǒng)疾病、中樞神經(jīng)系統(tǒng)疾病、呼吸系統(tǒng)疾病等多個(gè)治療領(lǐng)域，現(xiàn)由CSO招商團(tuán)隊(duì)全面轉(zhuǎn)型為自營銷售推廣團(tuán)隊(duì)。
泰凌醫(yī)藥以“服務(wù)健康生命”為使命，以誠信為基石，以創(chuàng)新為動力，追求卓越，以人為本，積極引進(jìn)優(yōu)秀的人才，立志成為卓越的醫(yī)藥健康企業(yè)，為人類的健康事業(yè)做出貢獻(xiàn)。
China NT Pharma Group Company Limited, founded in1995, a comprehensive listed pharmaceutical factory engaged in investment, R&D, production, marketing and promotion of medicines and new medicinal technologies (Stock Code: 01011. HK).Headquartered in Hong Kong, with marketing、research and medical business center based in Shanghai, Beijing and Guangzhou. Our main pharmaceutical manufacturing plants located in Suzhou, Taizhou, Changsha and Switzerland. Currently NT Pharma Group has more than 10 subsidiaries.
We focus on development of core products covering tumor and Hematological system, central nervous system, chronic, bone metabolic, generic pharmaceutical and other therapeutic fields. According to our strategy, now we have fully transformed into self-management model.
With the mission of “serving healthy life”, we take credibility as the cornerstone, innovation as the driving force, strive for excellence, and focused on human resources with talent，determined to become an excellent medical &health enterprise and contribute to human health.
歡迎訪問公司網(wǎng)站：http://www.ntpharma.com/